Inotrem Receives Milestone Funding From the Crohn’s & Colitis Foundation IBD Ventures Program to Advance Its Inflammatory Bowel Disease Pipeline
Funding was provided on the basis of strong interim data successfully supporting the company’s innovative approach targeting the TREM-1 pathway to treat chronic inflammatory conditions. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received the second milestone-based funding from......